Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
118 hedge funds and large institutions have $1.29B invested in Ra Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 21 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
43% more capital invested
Capital invested by funds: $900M → $1.29B (+$385M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
5% less funds holding
Funds holding: 124 → 118 (-6)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
80% less call options, than puts
Call options by funds: $388K | Put options by funds: $1.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$22.4M |
| 2 |
BlackRock
New York
|
+$20.3M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$14.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMPI
Morgenthaler Management Partners IX
Portola Valley,
California
|
-$27.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.78M |
| 3 |
Renaissance Technologies
New York
|
-$6.52M |
| 4 |
Millennium Management
New York
|
-$6.27M |
| 5 |
Two Sigma Investments
New York
|
-$3.86M |
RARX Hedge Fund Activity: Q2 2019 in Review
118 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q2 2019, worth a combined $1.29B — up 43% from $900M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of RARX and 17 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 55 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $22.4M. The largest seller was Morgenthaler Management Partners IX, exiting entirely with an estimated $27.5M sold.
- 118 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q2 2019, down from 124 in Q1 2019.
- Funds reported $1.29B of Ra Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 43% quarter-over-quarter.
- 17 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 21 closed out, a net change of -4 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Baker Bros. Advisors, an estimated $22.4M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was Morgenthaler Management Partners IX, an estimated $27.5M sold.
Based on aggregated 13F filings for Q2 2019.